Editorial board member Mario Cazzola (University of Rome Tor Vergata, Rome, Italy) discusses the background and findings of his late-breaking presentation entitled: Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis.
Questions1. Why was there a need for the meta analysis of inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) and LABA/long-acting muscarinic antagonist (LAMA) fixed dose combinations on lung function and exacerbation of chronic obstructive pulmonary disease (COPD)? (0:12)
2. What were the findings of this analysis? (0:49)
3. Which of the LAMA/LABA combinations were found to be the most effective? (1:37)
4. What (if any) were the limitations of this study? (2:27)
5. Which emerging LAMA/LABA combinations require further study? (3:22)
Speaker disclosure: Mario Cazzola has participated as a speaker, and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, Novartis, Pfizer, Verona Pharma, and Zambon, and is or has been a consultant to Chiesi Farmaceutici, Lallemand, Novartis, Verona Pharma, and Zambon.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018.